The company thinks a post-pandemic world will appreciate the need for genetic information more than before, but Invitae must navigate uncertainty in the meantime. On paper, there's tremendous ...
SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE:NVTA), a genetic information company, today announced that it has expanded its genetic testing offering with hundreds of additional genes and ...
Mutations to the BRCA1 and BRCA2 genes significantly increase the chances of breast and ovarian cancers, and a test can assess a person’s risk from those variants. But those genes are just two of the ...
Invitae’s business operations are heading to a new home. Under a bankruptcy auction, Labcorp was selected as the winning bidder for the firm’s genetic testing services, digital health solutions, and ...
What is a winner-take-most market? The long term profitability and success of any company is highly dependent on the market in which it operates. Many markets have low barriers to entry; many sellers ...
Outcomes4Me Inc., developer of a leading free mobile app and platform to navigate cancer treatment and care, has partnered with Invitae Corp., a leading medical genetics company, to expand education ...
Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankruptcy in the coming weeks. The San Francisco-based medical genetics ...
SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE: NVTA), a genetic information company, today announced it now offers genetic testing for neuromuscular diseases, including Duchenne/Becker ...
Last year, Invitae ($NVTA) said that it was aiming to expand its test menu to more than 1,000 genes by mid-2016. Now, the company has achieved that goal ahead of ...
Invitae Corporation (NYSE: NVTA), a genetic information company, has announced that it has more than doubled the size of its genetic testing platform to include more than 600 genes and will begin ...
A genetic testing company you've never heard of could become a household name as it takes on 23andMe
If the future of healthcare is in your DNA, there's a war brewing over how to harness the information it contains without causing harm to patients. Today, there are two main ways to take a peak at ...
In the past three months alone, shares of genetic testing company Invitae (NVTA +0.00%) have soared by 90%. In fact, the company's shares outperformed the S&P 500's return of 25% by nearly five times ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results